Evaluating a Decreased Dose of Radiation Therapy to the Elective Neck for the Treatment of HPV-Related Oropharyngeal Cancer, ENLIGHT Trial

This clinical trial evaluates how decreasing the dose of radiation to the elective neck (areas of lymph nodes not directly involved in the cancer) impacts treatment outcomes in patients with human papillomavirus (HPV)-related oropharyngeal cancer. Radiation therapy uses high energy x-rays, particles, or radioactive seeds to kill cancer cells and shrink tumors. Radiation therapy plays an important role in the treatment of HPV-related oropharyngeal cancer, but it also causes significant toxicities. Given the significant toxicities associated with treatment, and the excellent outcomes of HPV-rela

Trial Details

NCT ID
NCT07178301
Phase
PHASE2
Sponsor
Northwestern University
Status
RECRUITING
Cancer Type
HPV Positive Head and Neck Cancer
Interventions
  • Computed Tomography
  • Nasopharyngeal Laryngoscopy
  • Positron Emission Tomography
  • Questionnaire Administration
  • Radiation Therapy
Locations (sample)
  • Chicago, Illinois, United States|41.85003,-87.65005
  • Warrenville, Illinois, United States|41.81781,-88.1734

Key Eligibility Criteria

  • 1.1 Patients must have a histologically confirmed HPV-related OPSCC, confirmed by HPV insitu hybridization.
  • 1.2 Patients must not have received prior treatment (i.e., no induction chemotherapy).
  • 1.3 Patients must have evaluable disease (per RECIST v1.1 response criteria). See Section 6.
  • 3 for the evaluation of measurable disease.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find HPV Positive Head and Neck Cancer Trials on Trialify →